Navigation Links
Luminex MAGPIX System Shown to be More Cost Effective and Efficient Than Conventional ELISA Method in Initial Study
Date:9/8/2010

AUSTIN, Texas, Sept. 8 /PRNewswire-FirstCall/ -- Luminex Corporation (Nasdaq: LMNX), today announced that initial results from a study conducted at the NMI Natural and Medical Sciences Institute at the University of Tubingen in Germany demonstrate that its MAGPIX® system provides more cost effective and efficient results than a conventional microtiter plate based ELISA method.

(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100104/LUMINEXLOGO)

"These initial results demonstrate why MAGPIX could be a good choice for every research laboratory," said Dr. Thomas Joos, the head of the Biochemistry Department at the Natural and Medical Sciences Institute. "The system is a great choice for labs seeking one platform that allows the efficiency of multiplexing as well as the ability to run single tests, as needed. It can help labs save resources, increase efficiency and maximize results."

The NMI Natural and Medical Sciences Institute performed a comparative study between the recently launched MAGPIX system and a conventional ELISA method.  The study utilized an assay for soluble tumor necrosis factor receptor II to compare the analytical methods using several parameters including optimal detection antibody concentration, dynamic range and assay sensitivity, sample measurement, intra- and inter-assay precision, parallelism, and dilution linearity.  In addition to analytical performance, a time and motion analysis, and a cost comparison was performed.

The findings from this initial study demonstrate that MAGPIX provides accurate assay results at costs of as much as half of the microtiter plate ELISA method with equivalent sensitivity. While total assay and hands-on time for MAGPIX and ELISA were similar, MAGPIX is capable of producing up to 50 results in the same amount of time as one ELISA sample while requiring the same amount of sample material.

"We are very pleased with the findings of Dr. Joos's study at NMI, demonstrating strong performance of MAGPIX in relation to conventional ELISA testing," said Patrick J. Balthrop, president and CEO of Luminex.  "These initial data highlight the importance of MAGPIX as a scientific tool for any lab seeking to enhance productivity and bring the power of multiplexing to their day-to-day research."

Luminex's MAGPIX system is a compact analytical instrument capable of performing up to 50 tests on a single sample providing nearly 5,000 data points in under an hour. The easy-to-use and simple-to-deploy instrument was designed to meet the needs of scientists and researchers who have not been able to take advantage of the power of multiplexing because of resource or space limitations.

Based on Luminex's xMAP® Technology, MAGPIX provides fast, accurate and easily reproducible results and saves laboratory time and resources.  Like all of Luminex's instruments, it is versatile and flexible and can be used to analyze both nucleic acids and proteins, making it applicable in many research settings.

For more information on MAGPIX, call 512.219.8020, or visit www.luminexcorp.com/magpix.

About Luminex CorporationLuminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company's xMAP® multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics markets. The Company's xMAP Technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP Technology can be obtained at www.luminexcorp.com.Luminex Contacts:Harriss T. Currie, 512-219-8020Vice President, Finance and Chief Financial Officerhcurrie@luminexcorp.comMimi L. Torrington, 512-219-8020Director of Investor Relationsmtorrington@luminexcorp.comMedia:Nicole L. Cottrill, 615-327-7999ncottrill@seigenthaler.com
'/>"/>

SOURCE Luminex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Luminex Donates Companys First MAGPIX Multiplexing System to Papua New Guinea Institute of Medical Research
2. Luminex Announces Commercial Launch of New Cystic Fibrosis Test
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. CardioFocus Endoscopic Ablation System Earns CE Mark to Treat Atrial Fibrillation; US Clinical Investigation Underway
5. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
6. Syndicom SpineConnect Web Platform Chosen for Applied Spines Leg and Back Pain Clinical Trial of Its Stabilimax NZ(R) Dynamic Spine Stabilization System
7. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
8. New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
11. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
Breaking Medicine News(10 mins):